Daily pill aims to stop chronic migraine before it starts
NCT ID NCT07729462
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether taking rimegepant once daily can prevent migraine attacks in people with chronic migraine (15 or more headache days per month). About 400 adults will receive either rimegepant or a placebo for 12 weeks, then all participants may receive rimegepant for another 12 weeks. The study measures changes in monthly migraine days, medication use, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a daily tablet of rimegepant, a CGRP receptor antagonist
- What this could lead to
- If successful, this could offer a new once-daily option to prevent chronic migraine attacks, reducing headache days and improving quality of life.
- What could go wrong
- This is a phase 3 trial, so earlier results may not hold up. Rimegepant is already approved for episodic migraine, but its effectiveness and safety for chronic migraine are still being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTIVE TREATMENT OF MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hope Clinical Research
Canoga Park, California, 91303, United States
-
Neurology Offices of South Florida PLLC
Boca Raton, Florida, 33428, United States